Q3 2025 Stereotaxis Inc Earnings Call Transcript
Key Points
- Stereotaxis Inc (STXS) received FDA approval for the Genesis X system, marking a significant milestone in their robotic surgical technology.
- The company reported strong commercial interest and initial sales for the Magic Sweep high-density mapping catheter in the US, generating over $300,000 in revenue within the first two months of launch.
- Stereotaxis Inc (STXS) has a robust pipeline of innovation efforts, including multiple products in late stages of regulatory review, which are expected to strengthen commercial results.
- The company anticipates over 20% annual revenue growth for the full year 2025, driven by both system and recurring revenue streams.
- Stereotaxis Inc (STXS) maintains a healthy balance sheet with $10.5 million in cash and no debt, positioning them well for future growth and innovation.
- Operating loss and net loss for the third quarter of 2025 were $6.6 million and $6.5 million, respectively, indicating ongoing financial challenges.
- Gross margins remain impacted by fixed overhead allocated over low production levels, with system gross margin at only 19%.
- The company is still awaiting regulatory approval for key products like the Magic catheter in the US, which could delay full commercial launch and revenue realization.
- Recurring revenue growth is contingent on gaining further approvals and adoption of new catheters, which may face structural barriers in certain markets.
- Stereotaxis Inc (STXS) faces competition in the electrophysiology field, particularly with the rise of pulse field ablation technology, which could impact market share.
Good afternoon.
Thank you for joining us for Stir Taxes' 3rd quarter 2025 earns conference call. Certain statements during the conference call and question-and-answer period to follow may relate to future events, expectations, and as such constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1,995.
Such statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the company in the future to be materially different from the statements that the company's executives may may make today.
These risks are described in detail in our public filings within the Securities and Exchange Commission, including our latest periodic report on Form 10k or 10Q.
We assume no duty to update these statements. At this time, all participants have been placed on a listen-only mode. The floor will be open for questions and comments following the presentation. As a reminder, today's call is being recorded.
It is now my pleasure to turn the floor
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
